The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. ADMA Biologics's Revenue for the
three
months ended in Dec. 2023 was $73.9 Mil. ADMA Biologics's average Accounts Receivable for the
three
months ended in Dec. 2023 was $29.4 Mil.
Hence, ADMA Biologics's Receivables Turnover for the
three
months ended in Dec. 2023 was 2.52.
ADMA Biologics Receivables Turnover Historical Data
The historical data trend for ADMA Biologics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ADMA Biologics's Receivables Turnover
For the Biotechnology subindustry, ADMA Biologics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics's Receivables Turnover Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Receivables Turnover falls into.
ADMA Biologics Receivables Turnover Calculation
Receivables Turnover measures the number of times a company collects its average accounts receivable balance.
ADMA Biologics's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
ADMA Biologics Receivables Turnover Related Terms
Thank you for viewing the detailed overview of ADMA Biologics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.
ADMA Biologics (ADMA Biologics) Business Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMA has been successfully added to your 